卡培他滨维持治疗转移性结直肠癌的疗效分析

Clinical efficacy of capecitabine maintenance therapy for patients with metastatic colorectal cancer

目的观察转移性结直肠癌患者经含氟尿嘧啶类药物联合化疗控制病情后,行卡培他滨维持治疗的疗效及安全性。方法将75例化疗后获得控制的转移性结直肠癌患者分为两组,其中卡培他滨维持治疗组40例,停药观察组35例,观察两组患者的无进展生存期(PFS)和相关不良反应。结果卡培他滨维持治疗组患者的总体中位PFS为11.0个月,一线化疗后中位PFS为11.0个月,二线化疗后中位PFS为10.0个月;停药观察组患者的总体中位PFS为7.0个月,一线化疗后中位PFS为8.0个月,二线化疗后中位PFS为7.0个月,两组比较均有统计学差异(均P<0.05)。卡培他滨维持治疗组不良反应主要包括恶心、呕吐、血白细胞下降、手足综合征等,停药观察组不良反应轻微。卡培他滨维持治疗组不良反应发生率高于停药观察组,均有统计学差异(均P<0.05)。结论卡培他滨维持治疗转移性结直肠癌可获得较长PFS,患者耐受性良好。

Objective To observe the efficacy and safety of maintenance therapy with capecitabine （Xeloda） for patients with metastatic colorectal cancer （mCRC） who had responded to chemotherapy. Methods Seventy five mCRC patients, who had achieved objective remission from fluorouracil based chemotherapy were recruited, among whom 40 patients received a maintenance therapy with Xeloda （study group） and 35 patients stopped chemotherapy （control group）. The progress-free-survival （PFS） and adverse drug reactions （ADR） were documented and compared between two groups. Results The median PFS time in study and control groups was 11.0 months and 7.0 months, respectively （P〈0.05）. In study group, the median PFS time for first-line chemotherapy patients was 11.0 months and 10.0 months for second-line patients, while in control group the result was 8.0 months and 7.0 months, respectively. The common adverse effects in study group were nausea, vomiting, leucocytopenia, and hand-foot syndrome. Conclusion Patients with metastatic colorectal cancer receiving capecitabine maintenance therapy may achieve longer PFS following effective fluorouracil based chemotherapy with good tolerance and low toxicity.